Zacks Investment Research upgraded Novadaq Technologies Inc. (NASDAQ:NVDQ) to Hold in a report released today.
- Updated: October 11, 2016
Zacks Investment Research has upgraded Novadaq Technologies Inc. (NASDAQ:NVDQ) to Hold in a report released on 10/12/2016.
Previously on Thursday October 29, 2015, First Analysis Sec reported about Novadaq Technologies Inc. (NASDAQ:NVDQ) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.34%.
Yesterday Novadaq Technologies Inc. (NASDAQ:NVDQ) traded -1.96% lower at $10.77. The company’s 50-day moving average is $11.76 and its 200-day moving average is $10.79. The last stock close price is down -0.18% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 90,901 shares of the stock were exchanged, down from an average trading volume of 232,694
See Chart Below
Novadaq Technologies Inc. has a 52 week low of $8.26 and a 52 week high of $14.36 The company’s market cap is currently $0.
About Novadaq Technologies Inc. (NASDAQ:NVDQ)
Novadaq Technologies Inc. is a medical device company. The Company primarily develops, manufactures and markets real-time fluorescence imaging products that are designed for use by surgeons in the operating room and other clinical settings where open and minimally invasive surgery or interventional procedures are performed. The Company's segment is medical devices. The Company's SPY fluorescence imaging technology platform (SPY Fluorescence Imaging) provides clinically relevant anatomic and physiologic images of blood flow in vessels and micro-vessels during a range of surgical and outpatient procedures performed in the operating room or clinic. The Company's products include SPY, SPY Elite, LUNA and PINPOINT Imaging Systems, SPY Analysis Toolkit, DermACELL and SPY-Q Case Manager. DermACELL is an Acellular Dermal Matrix (ADM) that is used in breast reconstruction surgeries, as well as in the treatment of diabetic foot and venous stasis ulcers, and chronic non-healing wounds.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.